Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.
Marianne Pavel, MD
Advertisement
Articles by Marianne Pavel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
5